Lyra Therapeutics Inc’s filing revealed that its Executive Chair Waksal Harlan acquired Company’s shares for reported $74095.0 on Nov 10 ’23. In the deal valued at $2.96 per share,25,000 shares were bought. As a result of this transaction, Waksal Harlan now holds 261,966 shares worth roughly $1.41 million.
Then, PERCEPTIVE ADVISORS LLC bought 3,610,832 shares, generating $8,999,999 in total proceeds. Upon buying the shares at $2.49, the Director now owns 11,469,117 shares.
Before that, ANDERSON EDWARD T bought 1,805,416 shares. Lyra Therapeutics Inc shares valued at $4,387,161 were divested by the Director at a price of $2.43 per share. As a result of the transaction, ANDERSON EDWARD T now holds 2,521,745 shares, worth roughly $13.62 million.
A number of analysts have revised their coverage, including H.C. Wainwright’s analysts, who began to cover the stock in late August with a ‘”a Buy”‘ rating. Cantor Fitzgerald began covering LYRA with “an Overweight” recommendation on May 24, 2022. William Blair started covering the stock on May 26, 2020. It rated LYRA as “an Outperform”.
Price Performance Review of LYRA
On Tuesday, Lyra Therapeutics Inc [NASDAQ:LYRA] saw its stock jump 2.47% to $5.40. Over the last five days, the stock has gained 3.05%. Lyra Therapeutics Inc shares have risen nearly 3.05% since the year began. Nevertheless, the stocks have risen 125.94% over the past one year. While a 52-week high of $6.79 was reached on 03/27/24, a 52-week low of $1.93 was recorded on 01/24/24. SMA at 50 days reached $5.48, while 200 days put it at $4.24. A total of 0.24 million shares were traded, compared to the trading of 0.24 million shares in the previous session.
Levels Of Support And Resistance For LYRA Stock
The 24-hour chart illustrates a support level at 5.23, which if violated will result in even more drops to 5.07. On the upside, there is a resistance level at 5.52. A further resistance level may holdings at 5.65. The Relative Strength Index (RSI) on the 14-day chart is 46.84, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -0.21, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bearish at 75.14%. Stochastics %K at 20.36% indicates the stock is a holding.
The most recent change occurred on May 26, 2020 when Jefferies began covering the stock and recommended ‘”a Buy”‘ rating along with a $24 price target.
